The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.
Tema Obesity & Cardiometabolic ETF HRTS
Morningstar’s Analysis HRTS
Will HRTS outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 39.2
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Vertex Pharmaceuticals Inc | 5.39 | 3.3 Mil | Healthcare |
Amgen Inc | 5.34 | 3.3 Mil | Healthcare |
Eli Lilly and Co | 4.96 | 3.0 Mil | Healthcare |
Novo Nordisk A/S Class B | 4.70 | 2.9 Mil | Healthcare |
DexCom Inc | 4.25 | 2.6 Mil | Healthcare |
Insulet Corp | 3.07 | 1.9 Mil | Healthcare |
Crinetics Pharmaceuticals Inc | 2.96 | 1.8 Mil | Healthcare |
Cytokinetics Inc | 2.86 | 1.8 Mil | Healthcare |
Medtronic PLC | 2.83 | 1.7 Mil | Healthcare |
Edwards Lifesciences Corp | 2.80 | 1.7 Mil | Healthcare |